Author + information
- Yeo-Jeong Song1,
- Sang-Yong Yoo1,
- Won-Kyung Lee1,
- Woo-Dae Bang1,
- Sang Jin Ha1,
- Suk Min Seo1 and
- Sangsig Cheong1
Recently, a drug-eluting balloon (DEB) has emerged as a potential therapeutic option and has been widely adopted for treating in-stent restenosis. However, the benefits of DEB are still uncertain for de novo coronary lesions.
From January 2010 through April 2016, 171 consecutive patients with de novo coronary artery lesions underwent PCI using DEB. Major adverse cardiac events (MACEs) including cardiac death, non-fatal myocardial infarction (MI), Target-lesion revascularization (TLR), and Target vessel revascularization (TVR) were determined for all patients.
The rate of bailout-stenting was 3.5% due to type C dissection after pre-dilatation. Average DEB diameter and lengths were 2.4 ± 0.3 mm and 20.9 ± 4.4 mm, respectively. During the follow-up periods (mean 24 months, median 22.6 months), cardiac death, non-fatal MI, TLR, and TVR were occurred; 1 (0.6%) cardiac death, 4 (2.3%) non-fatal MI, 2 (1.2%) TLR, and 8 (4.7%) TVR, respectively. Cumulative MACEs rate was 6.4 % (11/175). Follow-up coronary angiography with QCA analysis was performed in 53 (31%) patients. Reference vessel diameter and minimal luminal diameters at follow-up were larger than that of immediate Post-procedure. Late luminal loss was -0.19 ± 0.39 mm (p=0.001). Cox regression analysis showed that the only factor for predicting unfavorable clinical outcomes was reference diameter less than 2.1 mm.
PCI with using DEB may be the effective alternative option for treating de novo coronary lesions with favorable long-term clinical outcomes. Larger randomized trials are needed to support the benefits of DEB related interventions.